Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
Status:
Recruiting
Trial end date:
2033-06-30
Target enrollment:
Participant gender:
Summary
Phase II, randomized, open-label, international, multicenter study to compare efficacy of
standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in
HR-positive/HER2-negative high/intermediate risk breast cancer patients